Blueprint Medicines Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has two approved drugs.
There are eight US patents protecting BLUEPRINT MEDICINES drugs.
There are one hundred and three patent family members on BLUEPRINT MEDICINES drugs in forty countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Blueprint Medicines
International Patents: | 103 |
US Patents: | 8 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Blueprint Medicines
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-003 | Jan 9, 2020 | RX | Yes | Yes | 9,944,651 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | 9,944,651 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-004 | Jun 16, 2021 | RX | Yes | No | 9,994,575 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 3096043 | ⤷ Sign Up |
South Africa | 201601970 | ⤷ Sign Up |
European Patent Office | 3057969 | ⤷ Sign Up |
China | 108473468 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Blueprint Medicines Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3057969 | C202130012 | Spain | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1473; DATE OF AUTHORISATION: 20200924; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1473; DATE OF FIRST AUTHORISATION IN EEA: 20200924 |
3057969 | 21C1013 | France | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925 |
3057969 | 2190008-9 | Sweden | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/20/1473 20200925 |
3057969 | C20210005 00320 | Estonia | ⤷ Sign Up | PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.